A novel method of interpretive structural modeling (ISM) using a DNA-based algorithm is proposed in this paper. ISM is commonly used when the current technology and its application to business administration, industrial and systems engineering, organizational behavior, etc., concern complicated or problematic issues, or situations among an element set of the given problem context for making decisions. When structuring a problem with a large number of elements in an ISM process, the crossings among elements should be minimized. This computationally complex minimization is NP-complete. The proposed algorithm describes how to calculate complex relations among elements to create a hierarchically restructured digraph. This paper also presents a new approach for applying a biological method to ISM to measure the efficiency of the algorithm in calculating a large number of elements for decision making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1109/TNB.2009.2023788 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path institute, Tucson, AZ, USA.
Background: To help improve the Alzheimer's disease (AD) therapeutics research and development process, the Critical Path for Alzheimer's Disease (CPAD) Consortium at the Critical Path Institute (C-Path) provides a neutral framework for the drug development industry, regulatory agencies, academia, and patient advocacy organizations to collaborate. CPAD's extensive track record of developing regulatory-grade quantitative drug development tools motivates sponsors to share patient-level data and neuroimages from clinical trials. CPAD leverages these data and uses C-Path's core competencies in data management and standardization, quantitative modeling, and regulatory science to develop tools that help de-risk decision making in AD drug development.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Background: The first disease-modifying treatments (DMTs) for Alzheimer's disease (AD) have been approved in the USA, marking profound changes in AD-diagnosis and treatment. This will bring new challenges in terms of clinician-patient communication. We aimed to collect the perspectives of memory clinic professionals regarding the most important topics to address and what (tools) would support professionals and their patients and care partners to engage in a meaningful conversation on whether (or not) to initiate treatment.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Numerous drugs (including disease-modifying therapies, cognitive enhancers and neuropsychiatric treatments) are being developed for Alzheimer's and related dementias (ADRD). Emerging neuroimaging modalities, and genetic and other biomarkers potentially enhance diagnostic and prognostic accuracy. These advances need to be assessed in real-world studies (RWS).
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
University of Pennsylvania, Philadelphia, PA, USA.
Background: People living with Alzheimer's disease and related dementias confront numerous decisions that affect their wellbeing, as well as that of their family members. Research demonstrates the importance of family involvement in such decision making, yet there is a lack of knowledge about how patients and families work together to make decisions and how families can best provide decisional support.
Methods: Semi-structured interviews were conducted separately with 15 patients diagnosed with mild cognitive impairment (MCI) or mild dementia, identified through a National Institute on Aging-funded Alzheimer's Disease Research Center, and 14 care partners.
Dementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Faculty of Health, University of Canberra, Bruce, ACT, Australia.
Background: There is a need to understand the benefits and limitations of innovative models of dementia care to ensure models meet the needs of people living with dementia, their families and staff. The aim of this scoping review was to explore and synthesise the barriers and facilitators to the widespread implementation of small-scale residential dementia care.
Method: A scoping review was conducted in 2023 in MEDLINE, CINAHL, PsycINFO, Scopus, Web of Science, and CENTRAL to identify empirical, peer-reviewed studies, published in English from database inception to October 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!